| Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. | |
| | |
MedLine Citation:
|
PMID: 16533193 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Chronic noncancer pain includes a heterogeneous group of disorders and is often refractory to treatment. Cannabis products have historically been used for chronic pain and are attracting renewed pharmaceutical interest. Nabilone is a synthetic cannabinoid licensed in Canada for the treatment of severe nausea and vomiting associated with cancer chemotherapy. We have used nabilone off-label for the treatment of chronic noncancer pain since 1999. In this article, we review our clinical experience of 20 adult patients with chronic noncancer pain who had been treated with nabilone and followed up for an average of 1.5 years. Prior to nabilone therapy, patients had used a wide range of therapies, including 11 who had used cannabis. Fifteen patients reported subjective overall improvement with nabilone, and nine reported reduced pain intensity. Beneficial effects on sleep and nausea were the main reasons for continuing use. Intolerable side effects were experienced in three patients (palpitations, urinary retention, dry mouth). Nabilone may be a useful addition to pain management and should be further evaluated in randomized controlled trials. |
| | |
Authors:
|
David M Berlach; Yoram Shir; Mark A Ware |
Related Documents
:
|
17315423 - A descriptive case series: oral transmucosal fentanyl use in patients with noncancerous... 16298063 - Risk factors for acute pain and its persistence following breast cancer surgery. 3041863 - Applications of hyperbaric oxygen for the otolaryngologist--head and neck surgeon. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pain medicine (Malden, Mass.) Volume: 7 ISSN: 1526-2375 ISO Abbreviation: Pain Med Publication Date: 2006 Jan-Feb |
Date Detail:
|
Created Date: 2006-03-14 Completed Date: 2006-06-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100894201 Medline TA: Pain Med Country: United States |
Other Details:
|
Languages: eng Pagination: 25-9 Citation Subset: IM |
Affiliation:
|
McGill University Medical School, McGill University Health Center, Montreal, Quebec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analgesics / administration & dosage, adverse effects Anti-Anxiety Agents / administration & dosage, adverse effects Arrhythmias, Cardiac / chemically induced Chronic Disease / psychology, therapy Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Male Middle Aged Nausea / drug therapy, etiology, physiopathology Pain Threshold / drug effects Pain, Intractable / drug therapy*, physiopathology, psychology Retrospective Studies Sleep / drug effects Sleep Disorders / drug therapy, etiology Sleep Stages Tetrahydrocannabinol / administration & dosage, adverse effects, analogs & derivatives* Treatment Outcome Urination Disorders / chemically induced Xerostomia / chemically induced |
| Chemical | |
Reg. No./Substance:
|
0/Analgesics; 0/Anti-Anxiety Agents; 1972-08-3/Tetrahydrocannabinol; 56496-90-3/nabilone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with h...
Next Document: Coping with cerebral palsy pain: a preliminary longitudinal study.